Priority Date: 16.01.12 (JP 20120006354)

MARKER PEPTIDE FOR DETERMINING RISK OF DEVELOPING METABOLIC SYNDROME AND USE THEREOF

  • Application ID: EP12866020
  • Status: The patent has been granted

Attorney

Employment test 51 - 200 employees
Company dna hoffmann eitle
operating since 1892
Headquarter in Munich and 6 offices
active in Legal Services and IP Portfolio Processing

Specialization

This EP application has the IPC combination C07, C12, and G01. We found, that TransMIT GmbH, Kailuweit & Uhlemann, dompatent von Kreisler Selting Werner - Partnerschaft von Patent- und Rechtsanwälten mbB, Avidity IP Ltd, Mewburn Ellis LLP and 61 others are specialized in this combination either. For a similar patent, they might be a good choice.

Timeline

  • 16.01.2012 - Priority Date (JP 20120006354)
  • 25.07.2013 - Publication A1 (WO2013108561)
  • 26.11.2014 - Publication A1 (EP2805966)
  • 12.07.2017 - Publication B1 (EP2805966)